demonstrated that although BRCA1/2-deficient TNBC is initially sensitive to DNA-damaging therapies, certain tumors may acquire secondary mutations that restore BRCA function, leading to resistance against platinum agents and PARP inhibitors (7).Efficient HR-mediated repair enables tumor cells to quickly resolve lethal DNA damage caused by chemotherapy or radiation, thereby avoiding elimination by both therapeutic agents and immune responses. This evidence concerns the gene BRCA1 and neoplasm.